Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Complications with current HIV antiretroviral therapy have left many children and adolescents
with limited therapeutic options due to drug resistance. The purpose of this study is to test
the effectiveness and safety of Vicriviroc (VCV), an HIV entry inhibitor and CCR5 co-receptor
antagonist.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)